NURIX THERAPEUTICS INC (NRIX) Stock News

USA - Nasdaq - NASDAQ:NRIX - US67080M1036 - Common Stock

21.47 USD

+3.38 (+18.68%)

Last: 12/8/2025, 4:32:31 PM

21.48 USD

+0.01 (+0.05%)

After Hours: 12/8/2025, 4:32:31 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NRIX Latest News, Press Relases and Analysis

All

Press Releases

9 hours ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

2 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual

7 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

13 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

a month ago - By: Benzinga

13 Analysts Have This To Say About Nurix Therapeutics

2 months ago - By: Benzinga

Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views

2 months ago - By: Stocktwits

News Image

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip

a month ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

a month ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

a month ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

a month ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

2 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

2 months ago - By: Nurix Therapeutics, Inc.

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

2 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

2 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

3 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

5 months ago - By: Stocktwits - Mentions: GILD

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)